ReviewCurrent atherosclerosis reports2026
Finerenone in Heart Failure with Preserved Ejection Fraction: Expanding the Role of Non-steroidal Mineralocorticoid Receptor Antagonists.
Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo evaluate the role of finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), in heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF). RECENT
findingsFinerenone has demonstrated cardiovascular and renal benefits in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), including reductions in hospitalizations for heart failure (HF). The FINEARTS-HF trial showed a reduced rate of worsening HF events in patients with left ventricular ejection fraction (LVEF) ≥40%, independent of CKD or T2D status. Preclinical studies suggest that antifibrotic and anti-inflammatory effects are distinct from those of steroidal MRAs. Ongoing trials are evaluating finerenone across various HF phenotypes and in combination with concomitant sodium-glucose cotransporter-2 inhibitors (SGLT2i). Finerenone is a promising therapy for HFpEF/HFmrEF, particularly in patients with the cardiovascular-kidney-metabolic syndrome (CKM). Hyperkalemia may potentially occur, especially in patients with reduced renal function, and requires monitoring and dose adjustments. Further studies are needed to identify which other HF and non-HF cohorts are most likely to benefit.
Indexed as
Identifiers
42593559What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.